Copyright © 2012 Sotirios D. Georgopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. P. Moayyedi and R. H. Hunt, “Helicobacter pylori public health implications,” Helicobacter, vol. 9, supplement 1, pp. 67–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
2. S. Suerbaum and P. Michetti, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 347, no. 15, pp. 1175–1186, 2002. View at Publisher · View at Google Scholar · View at Scopus
3. L. Fuccio, R. M. Zagari, L. H. Eusebi et al., “Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?” Annals of Internal Medicine, vol. 151, no. 2, pp. 121–128, 2009. View at Scopus
4. K. Fukase, M. Kato, S. Kikuchi et al., “Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial,” The Lancet, vol. 372, no. 9636, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
5. P. Malfertheiner, F. K. Chan, and K. E. McColl, “Peptic ulcer disease,” The Lancet, vol. 374, no. 9699, pp. 1449–1461, 2009. View at Publisher · View at Google Scholar · View at Scopus
6. A. Stathis, F. Bertoni, and E. Zucca, “Treatment of gastric marginal zone lymphoma of MALT type,” Expert Opinion on Pharmacotherapy, vol. 11, no. 13, pp. 2141–2152, 2010. View at Publisher · View at Google Scholar · View at Scopus
7. D. Y. Graham, “Antibiotic resistance in Helicobacter pylori: implications for therapy,” Gastroenterology, vol. 115, no. 5, pp. 1272–1277, 1998. View at Publisher · View at Google Scholar · View at Scopus
8. F. Mégraud, “H pylori antibiotic resistance: prevalence, importance, and advances in testing,” Gut, vol. 53, no. 9, pp. 1374–1384, 2004. View at Publisher · View at Google Scholar · View at Scopus
9. F. Megraud, “Helicobacter pylori and antibiotic resistance,” Gut, vol. 56, no. 11, p. 1502, 2007. View at Publisher · View at Google Scholar · View at Scopus
10. N. Broutet, S. Tchamgoué, E. Pereira, H. Lamouliatte, R. Salamon, and F. Mégraud, “Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients,” Alimentary Pharmacology & Therapeutics, vol. 17, no. 1, pp. 99–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
11. S. D. Georgopoulos, S. D. Ladas, S. Karatapanis et al., “Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin,” Digestive Diseases and Sciences, vol. 45, no. 1, pp. 63–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
12. “Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group,” Gut, vol. 41, no. 1, pp. 8–13, 1997. View at Scopus
13. T. Lind, S. V. van Zanten, P. Unge et al., “Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study,” Helicobacter, vol. 1, no. 3, pp. 138–144, 1996. View at Scopus
14. V. De Francesco, M. Margiotta, A. Zullo et al., “Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 783–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
15. J. P. Gisbert, R. Pajares, and J. M. Pajares, “Evolution of Helicobacter pylori therapy from a meta-analytical perspective,” Helicobacter, vol. 12, supplement 2, pp. 50–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
16. V. De Francesco, F. Giorgio, C. Hassan et al., “Worldwide H. pylori antibiotic resistance: a systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409–414, 2010. View at Scopus
17. L. A. Fischbach, K. J. Goodman, M. Feldman, and C. Aragaki, “Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis,” International Journal of Epidemiology, vol. 31, no. 1, pp. 128–139, 2002. View at Scopus
18. M. J. Janssen, A. H. Van Oijen, A. L. Verbeek, J. B. Jansen, and W. A. De Boer, “A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole,” Alimentary Pharmacology & Therapeutics, vol. 15, no. 5, pp. 613–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
19. R. J. Laheij, L. G. Rossum, J. B. Jansen, H. Straatman, and A. L. Verbeek, “Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis,” Alimentary Pharmacology & Therapeutics, vol. 13, no. 7, pp. 857–864, 1999. View at Publisher · View at Google Scholar · View at Scopus
20. P. Malfertheiner, F. Mégraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 2, pp. 167–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
21. P. H. Katelaris, G. M. Forbes, N. J. Talley, and B. Crotty, “A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study,” Gastroenterology, vol. 123, no. 6, pp. 1763–1769, 2002. View at Publisher · View at Google Scholar · View at Scopus
22. X. Calvet, J. Ducons, J. Guardiola et al., “One-week triple vs. quadruple therapy for Helicobacter pylori infection—a randomized trial,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 7, pp. 1261–1267, 2002. View at Publisher · View at Google Scholar · View at Scopus
23. J. Luther, P. D. Higgins, P. S. Schoenfeld, P. Moayyedi, N. Vakil, and W. D. Chey, “Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability,” American Journal of Gastroenterology, vol. 105, no. 1, pp. 65–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
24. D. Y. Graham and M. P. Dore, “Helicobacter pylori therapy demystified,” Helicobacter, vol. 16, no. 5, pp. 343–345, 2011.
25. W. D. Chey and B. C. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
26. M. Caselli, A. Zullo, G. Maconi et al., “‘Cervia II Working Group Report 2006’: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy,” Digestive and Liver Disease, vol. 39, no. 8, pp. 782–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
27. G. Maconi, C. Tosetti, G. Miroglio et al., “Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy,” Alimentary Pharmacology & Therapeutics, vol. 13, no. 11, pp. 1499–1504, 1999. View at Publisher · View at Google Scholar · View at Scopus
28. S. D. Georgopoulos, S. D. Ladas, S. Karatapanis et al., “Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies,” Alimentary Pharmacology & Therapeutics, vol. 16, no. 3, pp. 569–575, 2002. View at Publisher · View at Google Scholar · View at Scopus
29. G. J. Mantzaris, K. Petraki, E. Archavlis et al., “Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: 24-month follow-up study,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 11, pp. 1237–1243, 2002. View at Publisher · View at Google Scholar · View at Scopus
30. S. Karatapanis, S. D. Georgopoulos, V. Papastergiou, et al., “7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial,” Acta Gastroenterol Belg, vol. 74, no. 3, pp. 407–412, 2011.
31. T. Rokkas, P. Sechopoulos, I. Robotis, G. Margantinis, and D. Pistiolas, “Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen,” American Journal of Gastroenterology, vol. 104, no. 1, pp. 21–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
32. L. Boyanova, A. Mentis, M. Gubina et al., “The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe,” Clinical Microbiology and Infection, vol. 8, no. 7, pp. 388–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
33. Y. Glupczynski, F. Mégraud, M. Lopez-Brea, and L. P. Andersen, “European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 20, no. 11, pp. 820–823, 2001. View at Publisher · View at Google Scholar · View at Scopus
34. A. F. Mentis, E. Roma, A. Pangalis, and E. Katsiyiannakis, “Susceptibilities of Helicobacter pylori strains isolated from children with gastritis to selected antibiotics,” Journal of Antimicrobial Chemotherapy, vol. 44, no. 5, pp. 720–722, 1999. View at Publisher · View at Google Scholar · View at Scopus
35. J. P. Gisbert, J. L. Gisbert, S. Marcos, I. Jimenez-Alonso, R. Moreno-Otero, and J. M. Pajares, “Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 4, pp. 346–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
36. K. Seppälä, T. U. Kosunen, L. Veijola et al., “Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects,” Scandinavian Journal of Gastroenterology, vol. 43, no. 9, pp. 1149–1150, 2008. View at Publisher · View at Google Scholar · View at Scopus
37. L. Fuccio, R. M. Zagari, and F. Bazzoli, “What is the best salvage therapy for patients with Helicobacter pylori infection?” Nature Clinical Practice Gastroenterology and Hepatology, vol. 5, no. 11, pp. 608–609, 2008. View at Publisher · View at Google Scholar · View at Scopus
38. J. Q. Huang and R. H. Hunt, “Treatment after failure: the problem of ‘non-responders’,” Gut, vol. 45, supplement 1, pp. I40–I44, 1999. View at Scopus
39. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011.
40. D. Y. Graham, H. Lu, and Y. Yamaoka, “A report card to grade Helicobacter pylori therapy,” Helicobacter, vol. 12, no. 4, pp. 275–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
41. D. Y. Graham, “Efficient identification and evaluation of effective Helicobacter pylori therapies,” Clinical Gastroenterology and Hepatology, vol. 7, no. 2, pp. 145–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
42. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. J. P. Gisbert, X. Calvet, A. O'Connor, F. Mégraud, and C. A. O'Morain, “Sequential therapy for Helicobacter pylori eradication: a critical review,” Journal of Clinical Gastroenterology, vol. 44, no. 5, pp. 313–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
44. P. Moayyedi, “Sequential regimens for Helicobacter pylori eradication,” The Lancet, vol. 370, no. 9592, pp. 1010–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
45. N. S. Jafri, C. A. Hornung, and C. W. Howden, “Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment,” Annals of Internal Medicine, vol. 148, no. 12, pp. 923–931, 2008. View at Scopus
46. J. L. Tong, Z. H. Ran, J. Shen, and S. D. Xiao, “Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis,” Journal of Clinical Pharmacy and Therapeutics, vol. 34, no. 1, pp. 41–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
47. L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira, “Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children,” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3069–3079, 2009. View at Publisher · View at Google Scholar · View at Scopus
48. A. Zullo, V. De Francesco, C. Hassan, S. Morini, and D. Vaira, “The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis,” Gut, vol. 56, no. 10, pp. 1353–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
49. D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 8, pp. 556–563, 2007. View at Scopus
50. D. C. Wu, P. I. Hsu, J. Y. Wu, et al., “Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection,” Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36.e1–41.e1, 2010.
51. I. T. Paulsen, M. H. Brown, and R. A. Skurray, “Proton-dependent multidrug efflux systems,” Microbiological Reviews, vol. 60, no. 4, pp. 575–608, 1996. View at Scopus
52. M. A. Webber and L. J. Piddock, “The importance of efflux pumps in bacterial antibiotic resistance,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 9–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
53. M. C. Roberts, “Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics,” Molecular Biotechnology, vol. 28, no. 1, pp. 47–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
54. J. Molina-Infante, C. Pazos-Pacheco, and B. Perez-Gallardo, “Efficacy of nonbismuth quadruple “concomitant” therapy for H. pylori infection in a setting with high clarithromycin resistance,” Helicobacter, vol. 138, article 880, supplement 1, 2011.
55. J. Molina-Infante, B. Perez-Gallardo, M. Fernandez-Bermejo et al., “Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 10, pp. 1077–1084, 2010. View at Publisher · View at Google Scholar · View at Scopus
56. W. A. de Boer, E. J. Kuipers, and J. G. Kusters, “Sequential therapy; a new treatment for Helicobacter pylori infection: but is it ready for general use?” Digestive and Liver Disease, vol. 36, no. 5, pp. 311–314, 2004. View at Publisher · View at Google Scholar · View at Scopus
57. J. Sánchez-Delgado, X. Calvet, L. Bujanda, J. P. Gisbert, L. Titó, and M. Castro, “Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice,” American Journal of Gastroenterology, vol. 103, no. 9, pp. 2220–2223, 2008. View at Publisher · View at Google Scholar · View at Scopus
58. C. A. O'Morain and J. P. O'Connor, “Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection?” Nature Clinical Practice Gastroenterology and Hepatology, vol. 6, no. 1, pp. 8–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
59. P. Moayyedi and P. Malfertheiner, “Editorial: sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3081–3083, 2009. View at Publisher · View at Google Scholar · View at Scopus
60. J. Luther and W. D. Chey, “Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort?” Gastroenterology, vol. 136, no. 2, pp. 720–722, 2009. View at Publisher · View at Google Scholar · View at Scopus
61. W. H. Choi, D. I. Park, S. J. Oh et al., “Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea,” The Korean Journal of Gastroenterology, vol. 51, no. 5, pp. 280–284, 2008. View at Scopus
62. X. Z. Gao, X. L. Qiao, W. C. Song, X. F. Wang, and F. Liu, “Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication,” World Journal of Gastroenterology, vol. 16, no. 34, pp. 4357–4362, 2010. View at Publisher · View at Google Scholar · View at Scopus
63. E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., “14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial,” The Lancet, vol. 378, no. 9790, pp. 507–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
64. D. Y. Graham and E. Rimbara, “Understanding and appreciating sequential therapy for Helicobacter pylori eradication,” Journal of Clinical Gastroenterology, vol. 45, no. 4, pp. 309–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
65. H. G. Park, M. K. Jung, J. T. Jung, et al., “Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, pp. 56–65, 2012.
66. A. Merali and G. I. Leontiadis, “Sequential therapy—more studies are still required,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 1, pp. 194–195, 2012.
67. J. P. Gisbert and X. Calvet, “Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori,” Alimentary Pharmacology & Therapeutics, vol. 34, no. 6, pp. 604–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
68. H. Fakheri, T. Taghvaei, V. Hosseini, and Z. Bari, “A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial,” Helicobacter, vol. 17, no. 1, pp. 43–48, 2012.
69. D. Y. Graham and A. Shiotani, “New concepts of resistance in the treatment of Helicobacter pylori infections,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 5, no. 6, pp. 321–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
70. G. Treiber, J. Wittig, S. Ammon, S. Walker, L. J. van Doorn, and U. Klotz, “Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study),” Archives of Internal Medicine, vol. 162, no. 2, pp. 153–160, 2002. View at Scopus
71. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, “Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 2, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
72. L. A. Fischbach, L. E. Bravo, G. R. Zarama et al., “A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country,” Helicobacter, vol. 14, no. 2, pp. 100–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
73. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicilin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days,” Helicobacter, vol. 16, no. 2, pp. 146–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
74. S. Georgopoulos, V. Papastergiou, E. Xirouchakis, et al., “Evaluation of a four-drug, three-antibiotic, nonbismuth-containing “concomitant” therapy as first-line Helicobacter pylori eradication regimen in Greece,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011.
75. S. D. Georgopoulos, E. Xirouchakis, and F. Laoudi, “Clinical evaluation of a 10-day regimenwith esomeprazole, metronidazole, amoxycilline and clarithromycin for the eradication of Helicobacter pylori (E-MACH study),” Helicobacter, vol. 16, article A136, supplement 1, 2011.
76. J. M. Liou, J. T. Lin, C. Y. Chang et al., “Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design,” Gut, vol. 59, no. 5, pp. 572–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
77. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
78. L. A. Fischbach, S. van Zanten, and J. Dickason, “Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 10, pp. 1071–1082, 2004. View at Publisher · View at Google Scholar · View at Scopus
79. L. Fischbach and E. L. Evans, “Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori,” Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, pp. 343–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
80. S. Michopoulos, P. Tsibouris, H. Bouzakis et al., “Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-Iine Helicobacter pylori eradication regimens,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 6, pp. 737–744, 2000. View at Publisher · View at Google Scholar · View at Scopus
81. F. Perri, V. Festa, A. Merla, M. Quitadamo, R. Clemente, and A. Andriulli, “Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection,” Helicobacter, vol. 7, no. 2, pp. 99–104, 2002. View at Publisher · View at Google Scholar · View at Scopus
82. N. Garcia, X. Calvet, E. Gene, R. Campo, and E. Brullet, “Limited usefulness of a seven-day twice-a-day quadruple therapy,” European Journal of Gastroenterology and Hepatology, vol. 12, no. 12, pp. 1315–1318, 2000. View at Scopus
83. W. A. de Boer, R. J. van Etten, P. M. Schneeberger, and G. N. Tytgat, “A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule,” American Journal of Gastroenterology, vol. 95, no. 3, pp. 641–645, 2000. View at Publisher · View at Google Scholar · View at Scopus
84. W. A. de Boer, “A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule,” Expert Opinion on Investigational Drugs, vol. 10, no. 8, pp. 1559–1566, 2001. View at Publisher · View at Google Scholar · View at Scopus
85. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spénard, “Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial,” American Journal of Gastroenterology, vol. 98, no. 3, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
86. C. O'Morain, T. Borody, A. Farley et al., “Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study,” Alimentary Pharmacology & Therapeutics, vol. 17, no. 3, pp. 415–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
87. A. Saleem, A. Qasim, H. J. O'Connor, and C. A. O'Morain, “Pylera for the eradication of Helicobacter pylori infection,” Expert Review of Anti-Infective Therapy, vol. 7, no. 7, pp. 793–799, 2009. View at Publisher · View at Google Scholar · View at Scopus
88. P. Malfertheiner, F. Bazzoli, J. C. Delchier et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial,” The Lancet, vol. 377, no. 9769, pp. 905–913, 2011. View at Publisher · View at Google Scholar · View at Scopus
89. M. Romano, A. Cuomo, A. G. Gravina et al., “Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial,” Gut, vol. 59, no. 11, pp. 1465–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
90. M. Berning, S. Krasz, and S. Miehlke, “Should quinolones come first in Helicobacter pylori therapy?” Therapeutic Advances in Gastroenterology, vol. 4, no. 2, pp. 103–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
91. F. Perna, A. Zullo, C. Ricci, C. Hassan, S. Morini, and D. Vaira, “Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance,” Digestive and Liver Disease, vol. 39, no. 11, pp. 1001–1005, 2007. View at Publisher · View at Google Scholar · View at Scopus
92. P. Bogaerts, C. Berhin, H. Nizet, and Y. Glupczynski, “Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium,” Helicobacter, vol. 11, no. 5, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
93. J. J. Carothers, M. G. Bruce, T. W. Hennessy et al., “The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection,” Clinical Infectious Diseases, vol. 44, no. 2, pp. e5–e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
94. P. D. van der Linden, M. C. Sturkenboom, R. M. Herings, H. G. Leufkens, and B. H. Stricker, “Fluoroquinolones and risk of achilles tendon disorders: case-control study,” British Medical Journal, vol. 324, no. 7349, pp. 1306–1307, 2002. View at Scopus
95. K. F. Croom and K. L. Goa, “Levofloxacin: a review of its use in the treatment of bacterial infections in the United States,” Drugs, vol. 63, no. 24, pp. 2769–2802, 2003. View at Publisher · View at Google Scholar · View at Scopus
96. C. Bilardi, P. Dulbecco, P. Zentilin et al., “A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial,” Clinical Gastroenterology and Hepatology, vol. 2, no. 11, pp. 997–1002, 2004. View at Publisher · View at Google Scholar · View at Scopus
97. R. J. Saad, P. Schoenfeld, H. M. Kim, and W. D. Chey, “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 3, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
98. J. P. Gisbert, F. Bermejo, M. Castro-Fernández et al., “Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients,” American Journal of Gastroenterology, vol. 103, no. 1, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
99. J. P. Gisbert, “Second-line rescue therapy of Helicobacter pylori infection,” Therapeutic Advances in Gastroenterology, vol. 2, no. 6, pp. 331–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
100. J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero, and J. M. Pajares, “Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures,” Alimentary Pharmacology & Therapeutics, vol. 24, no. 10, pp. 1469–1474, 2006. View at Publisher · View at Google Scholar · View at Scopus
101. T. Nishizawa, H. Suzuki, and T. Hibi, “Quinolone-based third-line therapy for Helicobacter pylori eradication,” Journal of Clinical Biochemistry and Nutrition, vol. 44, no. 2, pp. 119–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
102. S. Karatapanis, L. Skorda, S. D. Georgopoulos et al., “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection,” Annals of Gastroenterology, vol. 22, no. 4, pp. 263–267, 2009. View at Scopus
103. C. Krystallis, D. Kamberoglou, D. Pistiolas et al., “A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study,” Digestive Diseases and Sciences, vol. 55, no. 12, pp. 3630–3631, 2010. View at Publisher · View at Google Scholar · View at Scopus
104. S. Pontone, M. Standoli, R. Angelini, and P. Pontone, “Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice,” Digestive and Liver Disease, vol. 42, no. 8, pp. 541–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
105. D. Y. Graham, M. S. Osato, J. Hoffman et al., “Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 6, pp. 745–750, 2000. View at Publisher · View at Google Scholar · View at Scopus
106. B. H. Lee, N. Kim, T. J. Hwang et al., “Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea,” Helicobacter, vol. 15, no. 1, pp. 38–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
107. Q. Sun, X. Liang, Q. Zheng et al., “High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication,” Helicobacter, vol. 15, no. 3, pp. 233–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
108. D. Y. Graham, S. U. Javed, S. Keihanian, S. Abudayyeh, and A. R. Opekun, “Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States,” Journal of Gastroenterology, vol. 45, no. 8, pp. 816–820, 2010. View at Scopus
109. E. Rimbara, L. A. Fischbach, and D. Y. Graham, “Optimal therapy for Helicobacter pylori infections,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 2, pp. 79–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
110. J. P. Gisbert and X. Calvet, “Review article: rifabutin in the treatment of refractory Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 2, pp. 209–221, 2012.
111. G. Treiber, S. Ammon, P. Malfertheiner, and U. Klotz, “Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures,” Helicobacter, vol. 7, no. 4, pp. 225–231, 2002. View at Publisher · View at Google Scholar · View at Scopus
112. P. Malfertheiner, F. Megraud, C. A. O'Morain, et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012.